All In MedTech

FDA Clearance Tracker · P150028

CHEATHAM PLATINUM (CP) STENT SYSTEM (Covered CP Stent, Covered Mounted CP Stent, CP Stent, Mounted CP Stent)

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Mar 25, 2016 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Mar 25, 2016

Approved

Time to decision

233 days

Received Aug 5, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P150028
Device name
CHEATHAM PLATINUM (CP) STENT SYSTEM (Covered CP Stent, Covered Mounted CP Stent, CP Stent, Mounted CP Stent)
Applicant
NuMED, Inc.
Applicant location
Hopkinton, NY
Received
Aug 5, 2015
Decided
Mar 25, 2016
Decision
Approved
Expedited review
Yes, flagged as expedited in FDA's record.
Supplements
7 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code PNF

FDA's approval statement

As written in FDA's record.

Approval for the Cheatham Platinum (CP) Stent System, including the CP Stent, Mounted CP Stent, Covered CP Stent, and Covered Mounted CP Stent. The CP Stent and Mounted CP Stent are indicated for use in the treatment of native and/or recurrent coarctation of the aorta involving a compliant aortic isthmus or first segment of the descending aorta where there is adequate size and patency of at least one femoral artery and balloon angioplasty is contraindicated or predicted to be ineffective.The Covered CP Stent and Covered Mounted CP Stent are indicated for use in the treatment of native and/or recurrent coarctation of the aorta involving the aortic isthmus or first segment of the descending aorta where there is adequate size and patency of at least one femoral artery associated with one or more of the following: Acute or chronic aortic wall injury; Nearly atretic descending aorta of 3 mm or less in diameter; A non-compliant stenotic aortic segment found on pre-stent balloon dilation; A genetic or congenital syndrome associated with aortic wall weakening or ascending aortic aneurysm.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code PNF (Aortic stent).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for NuMED, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.